3 results about "Glycated protein" patented technology

The invention relates to the technical field of in-vitro detection reagents, in particular to a preparation method of a glycated protein control product, the glycated protein control product and application of the glycated protein control product. By improving the preparation process of the glycated protein control product, removing free glucose after saccharification incubation and combining a secondary incubation process, unstable intermediates in the protein glycosylation process are reduced, and the quality of the glycated protein control product is improved. The stability of the glycated protein quality control product is improved, excessive functional components do not need to be added, and the method can be suitable for different detection methodology platforms.

This application discloses a predictive model, method, and system for cardiovascular complications in peritoneal dialysis patients based on glycated proteomics and machine learning. This application utilizes techniques such as glycated peptide enrichment, high-throughput glycated proteomics detection, targeted absolute quantification, and machine learning modeling to construct a predictive model suitable for assessing the risk of CVD complications in peritoneal dialysis patients. This model organically integrates glycated peptide biomarkers with clinical indicators, enabling early identification and stratified management of cardiovascular risk in peritoneal dialysis patients, and has good clinical application potential.

Title: Method of detection of glycated proteins in biological samples and use thereof The present invention relates to a method of detection of glycated proteins, particularly gHSA, which comprises the steps of: i) providing anthracene boronic acid methacrylate (ABAM): 10-[N-methyl-N-(o- boronobenzyl)aminomethyl]-anthracene-9-methyl methacrylate; ii) preparing a solution of ABAM in a biocompatible buffer with pH in the range of from 6.5 to 8.5 or in in vitro blood plasma sample of a healthy subject; iii) measuring initial fluorescence intensity of ABAM solution from step ii) at the wavelength of from 410 to 520 nm; iv) in vitro mixing of a known amount of ABAM solution from step ii) with a known amount of biological sample; v) measuring fluorescence intensity of the mixture from step iv) at the wavelength of from 410 to 520 nm; vi) determining the fluorescence intensity increases between the initial control fluorescence intensity measured in step iii) and the fluorescence intensity of the mixture of ABAM and biological sample measured in step v); vii) calculating the amount of glycated proteins in the biological sample. The present invention further relates to the use of this method in determination of the total concentrations of glycated proteins, particularly gHSA, in plasma samples and diagnostics for diabetes mellitus.